Literature DB >> 31772980

Extended Volumetric Follow-up of Juvenile Pilocytic Astrocytomas Treated with Proton Beam Therapy.

Edward M Mannina1, Greg K Bartlett1, Kevin P McMullen1.   

Abstract

PURPOSE: To describe volume changes following proton beam therapy (PBT) for juvenile pilocytic astrocytoma (JPA), we analyzed post-PBT magnetic resonance imaging (MRI) to clarify survivorship, response rate, and the concept of pseudoprogression.
MATERIALS AND METHODS: Pediatric patients with a histologic diagnosis of JPA after a biopsy or subtotal resection and at least 4 post-PBT MRIs were retrospectively reviewed. After PBT, tumors were contoured on follow-up T1-contrasted MRIs, and 3-dimensional volumes were plotted against time, with thresholds for progressive disease and partial response. Patterns of response, pseudoprogression, and progression were uncovered. Post-PBT clinical course was described by the need for further intervention and survivorship.
RESULTS: Fifteen patients with a median of 10 follow-up MRIs made up this report: 60% were heavily pretreated with multiple lines of chemotherapy, and 67% had undergone subtotal resection. With a median follow-up of 55.3 months after a median of 5400 centigray equivalents PBT, estimates of 5-year overall survival and intervention-free survival were 93% and 72%, respectively. The crude response rate of 73% included pseudoprogressing patients, who comprised 20% of the entire cohort; the phenomenon peaked between 3 and 8 months and resolved by 18 months. One nonresponder expired from progression. Post-PBT intervention was required in 53% of patients, with 1 patient resuming chemotherapy. There were no further resections or radiotherapy. One patient developed acute lymphoblastic leukemia, and another developed biopsy-proven radionecrosis.
CONCLUSION: The PBT for inoperable/progressive JPA provided 72% 5-year intervention-free survival in heavily pretreated patients. Although most patients responded, 20% demonstrated pseudoprogression. The need for post-PBT surveillance for progression and treatment-induced sequelae should not be underestimated in this extended survivorship cohort. © Copyright 2016 International Journal of Particle Therapy.

Entities:  

Keywords:  juvenile pilocytic astrocytoma; proton beam therapy; pseudoprogression

Year:  2016        PMID: 31772980      PMCID: PMC6871611          DOI: 10.14338/IJPT-16-00020.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  24 in total

1.  Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.

Authors:  Ashray Gunjur; Eddie Lau; Yamna Taouk; Gail Ryan
Journal:  J Med Imaging Radiat Oncol       Date:  2011-12       Impact factor: 1.735

2.  Scan pattern optimization for uniform proton beam scanning.

Authors:  Vladimir A Anferov
Journal:  Med Phys       Date:  2009-08       Impact factor: 4.071

3.  Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.

Authors:  Kimberly A Foster; William J Ares; Ian F Pollack; Regina I Jakacki
Journal:  Pediatr Blood Cancer       Date:  2014-11-08       Impact factor: 3.167

4.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Authors:  M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

5.  Spurious progression in pediatric brain tumors.

Authors:  Sheema Chawla; David N Korones; Michael T Milano; Ali Hussain; Abdel R Hussien; Ann G Muhs; Manisha Mangla; Howard Silberstein; Sven Ekholm; Louis S Constine
Journal:  J Neurooncol       Date:  2012-01-12       Impact factor: 4.130

6.  Management of pilocytic astrocytoma.

Authors:  T Kayama; T Tominaga; T Yoshimoto
Journal:  Neurosurg Rev       Date:  1996       Impact factor: 3.042

7.  Postoperative radiotherapy of supratentorial low-grade gliomas.

Authors:  E G Shaw; B W Scheithauer; D T Gilbertson; D A Nichols; E R Laws; J D Earle; C Daumas-Duport; J R O'Fallon; R P Dinapoli
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

8.  Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.

Authors:  Astrid K Gnekow; Fabian Falkenstein; Stephan von Hornstein; Isabella Zwiener; Susanne Berkefeld; Brigitte Bison; Monika Warmuth-Metz; Pablo Hernáiz Driever; Niels Soerensen; Rolf-D Kortmann; Torsten Pietsch; Andreas Faldum
Journal:  Neuro Oncol       Date:  2012-08-31       Impact factor: 12.300

9.  First experiences in treatment of low-grade glioma grade I and II with proton therapy.

Authors:  Henrik Hauswald; Stefan Rieken; Swantje Ecker; Kerstin A Kessel; Klaus Herfarth; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2012-11-09       Impact factor: 3.481

10.  Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data.

Authors:  Stephanie E Combs; Kerstin A Kessel; Klaus Herfarth; Alexandra Jensen; Susanne Oertel; Claudia Blattmann; Swantje Ecker; Angelika Hoess; Eike Martin; Olaf Witt; Oliver Jäkel; Andreas E Kulozik; Jürgen Debus
Journal:  Radiat Oncol       Date:  2012-10-17       Impact factor: 3.481

View more
  2 in total

1.  Pseudoprogression in pediatric low-grade glioma after irradiation.

Authors:  Derek S Tsang; Erin S Murphy; John T Lucas; Pagona Lagiou; Sahaja Acharya; Thomas E Merchant
Journal:  J Neurooncol       Date:  2017-07-27       Impact factor: 4.130

2.  Pseudoprogression in low-grade glioma.

Authors:  Jason M Slater; Helen A Shih
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.